BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 28838808)

  • 1. Characterization of structurally novel G protein biased CB
    Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
    Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ
    Ford BM; Cabanlong CV; Tai S; Franks LN; Penthala NR; Crooks PA; Prather PL; Fantegrossi WE
    J Pharmacol Exp Ther; 2019 May; 369(2):259-269. PubMed ID: 30833484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigating selectivity and bias for G protein subtypes and β-arrestins by synthetic cannabinoid receptor agonists at the cannabinoid CB
    Ryalls B; Patel M; Sparkes E; Banister SD; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Apr; 222():116052. PubMed ID: 38354957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biased Agonism and Biased Allosteric Modulation at the CB1 Cannabinoid Receptor.
    Khajehali E; Malone DT; Glass M; Sexton PM; Christopoulos A; Leach K
    Mol Pharmacol; 2015 Aug; 88(2):368-79. PubMed ID: 26044547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons.
    Laprairie RB; Bagher AM; Kelly ME; Dupré DJ; Denovan-Wright EM
    J Biol Chem; 2014 Sep; 289(36):24845-62. PubMed ID: 25037227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs.
    Franks LN; Ford BM; Madadi NR; Penthala NR; Crooks PA; Prather PL
    Eur J Pharmacol; 2014 Aug; 737():140-8. PubMed ID: 24858620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists.
    Patel M; Manning JJ; Finlay DB; Javitch JA; Banister SD; Grimsey NL; Glass M
    Biochem Pharmacol; 2020 May; 175():113871. PubMed ID: 32088263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays.
    Grafinger KE; Vandeputte MM; Cannaert A; Ametovski A; Sparkes E; Cairns E; Juchli PO; Haschimi B; Pulver B; Banister SD; Stove CP; Auwärter V
    Drug Test Anal; 2021 Jul; 13(7):1412-1429. PubMed ID: 33908179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor.
    Zagzoog A; Brandt AL; Black T; Kim ED; Burkart R; Patel M; Jin Z; Nikolaeva M; Laprairie RB
    Sci Rep; 2021 May; 11(1):10611. PubMed ID: 34012003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of receptor redistribution and beta-arrestin recruitment assays for the cannabinoid receptor 1.
    van der Lee MM; Blomenröhr M; van der Doelen AA; Wat JW; Smits N; Hanson BJ; van Koppen CJ; Zaman GJ
    J Biomol Screen; 2009 Aug; 14(7):811-23. PubMed ID: 19520790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
    Sachdev S; Banister SD; Santiago M; Bladen C; Kassiou M; Connor M
    Pharmacol Res Perspect; 2020 Apr; 8(2):e00566. PubMed ID: 32101383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.
    Conroy JL; Free RB; Sibley DR
    ACS Chem Neurosci; 2015 Apr; 6(4):681-92. PubMed ID: 25660762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct roles of β-arrestin 1 and β-arrestin 2 in ORG27569-induced biased signaling and internalization of the cannabinoid receptor 1 (CB1).
    Ahn KH; Mahmoud MM; Shim JY; Kendall DA
    J Biol Chem; 2013 Apr; 288(14):9790-9800. PubMed ID: 23449980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice.
    Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M
    Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors.
    Franklin JM; Vasiljevik T; Prisinzano TE; Carrasco GA
    Pharmacol Res; 2013 Feb; 68(1):46-58. PubMed ID: 23174265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPCR kinase subtype requirements for arrestin-2 and -3 translocation to the cannabinoid CB
    Manning JJ; Finlay DB; Glass M
    Biochem Pharmacol; 2024 Jun; 224():116190. PubMed ID: 38604257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protocol to Study β-Arrestin Recruitment by CB1 and CB2 Cannabinoid Receptors.
    Soethoudt M; van Gils N; van der Stelt M; Heitman LH
    Methods Mol Biol; 2016; 1412():103-11. PubMed ID: 27245896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Characterization of µ-Opioid Receptor Agonists with Biased G Protein or β-Arrestin Signaling, and Computational Study of Conformational Changes during Receptor Activation.
    Piekielna-Ciesielska J; Artali R; Azzam AAH; Lambert DG; Kluczyk A; Gentilucci L; Janecka A
    Molecules; 2020 Dec; 26(1):. PubMed ID: 33375124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.